Section to complete information about primary and secondary outcomes including. It includes the metric or method of measurement used and, the time point for every outcome.
Primary outcome(s):
Therapeutic efficacy:
1) Minimal Clinically Important Improvement-MCII (defined as the smallest change in measurement that signifies an important improvement in a patient’s symptom (VAS, WOMAC, Clinical Rasmussen, RAPID3). It will be calculated through a dichotomous score per outcome, based on 30% improvement from the baseline). Measurement time: baseline, at 90, 180 and 360 days.
2) Patient Acceptable Symptom State-PASS (defined as the value of symptoms the patient considers to be the thresholds of well-being for pain and function. This will be assessed with the following question: “Taking into account all your daily activities, do you consider your current state satisfactory in relation to pain level and functional impairment?” The response options are “Yes” or “No”). Measurement time: baseline, at 90, 180 and 360 days.
Key secondary outcomes:
1) Adverse Events (According to Common Terminology of Criteria for Adverse Events (CTCAE) version 3. Bone necrosis or tissues adjacent to the lesion, bone or muscle changes not compatible with a normal anatomy, muscle weakness, nausea, skin atrophy, ecchymosis, changes in skin pigmentation, fibrosis , alterations in the state of consciousness, pain in the area of application, neurological events, alterations in the liver enzymes or blood count, bone fracture, cardiovascular events). Measurement time: baseline, at 30, 90, 180 and 360 days.
2) Change in anti-inflammatory non steroidal drugs use. Measurement time: baseline, at 90, 180 and 360 days.